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A complex molecular switch directs
stress-induced cyclin C nuclear release through
SCFGrr1-mediated degradation of Med13
David C. Stiega, Stephen D. Willisa, Vidyaramanan Ganesana, Kai Li Ongb, Joseph Scuorzoc,†,
Mia Songc, Julianne Groseb, Randy Stricha, and Katrina F. Coopera,*
a

Department of Molecular Biology, Graduate School of Biological Sciences, and cSchool of Osteopathic Medicine,
Rowan University, Stratford, NJ 08084; bDepartment of Microbiology and Molecular Biology, Brigham Young
University, Provo, UT 84602

ABSTRACT In response to oxidative stress, cells decide whether to mount a survival or cell
death response. The conserved cyclin C and its kinase partner Cdk8 play a key role in this
decision. Both are members of the Cdk8 kinase module, which, with Med12 and Med13, associate with the core mediator complex of RNA polymerase II. In Saccharomyces cerevisiae,
oxidative stress triggers Med13 destruction, which thereafter releases cyclin C into the cytoplasm. Cytoplasmic cyclin C associates with mitochondria, where it induces hyperfragmentation and regulated cell death. In this report, we show that residues 742–844 of Med13’s
600–amino acid intrinsic disordered region (IDR) both directs cyclin C-Cdk8 association and
serves as the degron that mediates ubiquitin ligase SCFGrr1-dependent destruction of Med13
following oxidative stress. Here, cyclin C-Cdk8 phosphorylation of Med13 most likely primes
the phosphodegron for destruction. Next, pro-oxidant stimulation of the cell wall integrity
pathway MAP kinase Slt2 initially phosphorylates cyclin C to trigger its release from Med13.
Thereafter, Med13 itself is modified by Slt2 to stimulate SCFGrr1-mediated destruction. Taken
together, these results support a model in which this IDR of Med13 plays a key role in controlling a molecular switch that dictates cell fate following exposure to adverse environments.
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INTRODUCTION
Protein–protein interactions are at the heart of nearly all facets of
cell physiology, including transducing exogenous signals necessary
for proper cell fate decisions to be adopted. For example, following
exposure to cytotoxic compounds, the cell must assess the level of
damage and decide whether to arrest cell division and repair the
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damage or execute programmed cell death. Recently, it has become apparent that intrinsic-disordered regions (IDRs), defined by a
continuous stretch of disordered promoting residues, play key roles
in directing protein−protein interaction networks, especially those
involved in macromolecular decisions including signaling and control pathways (reviewed in Dyson and Wright, 2005; Fuxreiter et al.,
2014). This hotspot for communication is achieved in part by the
ability of IDRs to contribute to the formation of large, malleable
interfaces that can interact with multiple partners. These protein
interactions can occur via short segments termed molecular recognition features (MoRFs) that undergo disorder-to-order transition
upon binding to their cognate ligands (Fuxreiter et al., 2007). Consistent with these domains being communication hubs, the binding
of IDRs to their targets is often regulated by covalent modifications
including phosphorylation, which can serve as simple biological
switches (Vuzman et al., 2012).
In budding yeast, cyclin C and its kinase partner Cdk8 are predominantly negative regulators of a diverse set of stress response
genes (Surosky et al., 1994; Cooper et al., 1997; Holstege et al.,
1998; Chi et al., 2001; van de Peppel et al., 2005). Together with
363

Med13 and Med12, they form the Cdk8 kinase module (CKM) of the
multisubunit Mediator complex, which acts as an interface between
DNA bound transcription factors and RNA polymerase (Bourbon,
2008; Yin and Wang, 2014; Allen and Taatjes, 2015). In addition to
its transcriptional role, cyclin C possesses another function following
oxidative stress that is found in both yeast and mammalian cells
(Cooper et al., 2012, 2014; Strich and Cooper, 2014; Wang et al.,
2015). Specifically, nuclear release of cyclin C, but not Cdk8, allows
its relocalization to the mitochondrial outer membrane. At this new
subcellular address, cyclin C is necessary and sufficient for stressinduced mitochondrial fission and is required for MOMP-dependent
normal regulated cell death (RCD) execution (Cooper et al., 2012,
2014; Wang et al., 2015). This type of cell death is the reclassification of programmed cell death (PCD) passed by the international
Nomenclature Committee on Cell Death in 2015 (Galluzzi et al.,
2015). In budding yeast, cyclin C release is dependent on its direct
phosphorylation by Slt2 MAPK (Jin et al., 2014) and the ubiquitinmediated degradation of Med13 (Khakhina et al., 2014, and see
Figure 1) In the CKM, Med13 contains a large centrally located IDR,
the extent and placement of which is conserved across metazoans,
plants, and fungi (Nagulapalli et al., 2016). As Med13 also bridges
the CKM to the Mediator complex (Knuesel et al., 2009a) this centrally placed IDR may provide structural plasticity, allowing the CKM
to interface with different mediator components according to the
environment. Consistent with Med13 IDR being a potential communication hub, computer predictions suggest the presence of several MoRFs that are biased toward an alpha helical confirmation
(Toth-Petroczy et al., 2008).

FIGURE 1: Cdk8 module (Cdk8, cyclin C, Med12 and Med13)
regulation by the CWI MAPK pathway. H2O2 stimulates cell wall
sensors, leading to activation of the CWI MAP kinase module. Slt2
phosphorylation triggers cyclin C translocation to the mitochondria
and Med13 degradation (Khakhina et al., 2014). The pseudokinase
Kdx1 is also required for cyclin C nuclear release via an unknown
mechanism (Jin et al., 2014). Med12 is not required for cyclin C
nuclear release (Khakhina et al., 2014).
364 | D. C. Stieg et al.

In this report, we provide mechanistic details on how Med13 is
targeted for destruction following oxidative stress in the budding
yeast Saccharomyces cerevisiae. We show that the cell walI integrity
(CWI) pathway MAPK Slt2 directly phosphorylates Med13, which is
required for its recognition by the SCFGrr1 E3 ligase complex. Consistent with other SCF targets in yeast and higher eukaryotes (reviewed in Ang and Wade Harper, 2005), degradation of Med13 by
SCFGrr1 also requires phosphorylation by cyclin C-Cdk8, which most
likely primes this phosphodegron. Furthermore, this phosphodegron partly overlaps with the predicted Med13 IDR (Toth-Petroczy
et al., 2008). Consistent with this region serving as an interaction
hub (Uversky, 2013), this IDR directs both Cdk8 and Grr1 binding
and is sufficient to retain cyclin C in the nucleus. Taken together,
these results define a multistep switch required for the cellular decision to release cyclin C from the nucleus and identify a Med13 IDR
as the communication hub that coordinates this prodeath decision.

RESULTS
SCFGrr1 is necessary for Med13 H2O2-mediated degradation

We have previously shown that Med13 degradation is dependent
on a functional 26S proteasome, indicating that a ubiquitin ligase is required (Khakhina et al., 2014). In unstressed human cells,
Med13 is turned over by the conserved SCF ubiquitin ligase utilizing
the Fbw7 F-box recognition protein (Davis et al., 2013). Grr1, a yeast
homologue of Fbw7, is a nonessential F-box protein that utilizes a
leucine-rich region (LRR; Figure 2A) for substrate recognition (Flick
and Johnston, 1991; Hsiung et al., 2001). SCFGrr1 is necessary for
degradation of the mediator component Med3 (Gonzalez et al.,
2014), as well as proteins regulating the glycolytic–gluconeogenic
switch (Benanti et al., 2007). More recently, it has also been shown
to regulate Whi7, a repressor of Start transcriptional gene expression (Gomar-Alba et al., 2017). To determine whether SCFGrr1 plays
a role in H2O2-induced Med13 degradation, we examined Med13
protein levels following 0.4 mM H2O2 treatment in wild-type and
grr1∆ cells harboring functional Med13-HA on a single copy plasmid. This concentration of H2O2 has long been established to induce a MOMP-dependent RCD response in yeast (Madeo et al.,
1999; Carmona-Gutierrez et al., 2010; Galluzzi et al., 2011), as well
as triggering cyclin C nuclear release (Cooper et al., 2012, 2014; Jin
et al., 2014; Khakhina et al., 2014). The results (Figure 2B) show that
Med13-HA is significantly more stable in grr1∆ cells. We next repeated these experiments using endogenous MED13 tagged with
the myc epitope in wild-type (RSY1798) and grr1∆ mutant strains
(RSY1771) harboring a plasmid expressing either wild-type GRR1, a
vector control, or a GRR1 derivative deleted for the LRR domain
(grr1∆L) (Hsiung et al., 2001). Following H2O2 treatment, Med13myc was again significantly more stable in grr1∆ cells harboring
either the vector control or grr1∆L than in wild-type cells (Figure 2C
and Supplemental Figure S1A). These results suggest that SCFGrr1 is
the E3 ligase responsible for mediating Med13 degradation following H2O2 stress.
If SCFGrr1 is the ubiquitin ligase directing Med13 proteolysis, then
Grr1 should interact with Med13. To test this possibility, Grr1 and
Med13 association was assayed using a two-hybrid strategy. This approach has been used previously both to identify and confirm Grr1
substrates (Wang and Solomon, 2012; Gonzalez et al., 2014). We
expressed either the wild-type or the grr1∆L mutant GRR1 allele
fused to the Gal4 DNA-binding domain bait with the full-length
Med13 fused to the activator domain (AD) prey. These studies revealed that Grr1 interacts with Med13, and this interaction survives
addition of the histidine analogue 3-amino-1,2,4-triazole (3-AT), suggesting that the HIS3 reporter gene induction is robust (Figure 2D).
Molecular Biology of the Cell

The intrinsic disordered region of
Med13 interacts with Grr1
Many SCF targets require phosphorylated
substrates for F-box recognition (Skowyra et
al., 1997). Consistent with this model, the
LRR of Grr1 specifically recognizes phosphorylated serine/threonine–proline motifs
within its substrate degron (Hsiung et al.,
2001). In human cells, phosphorylation of
T326 is required for Med13 destruction by
SCFFbw7 (Davis et al., 2013). To address
whether a similar mechanism directs H2O2induced Med13 degradation in yeast, the
requirement of the analogous threonine in
yeast (T210; Supplemental Figure S1B) was
tested. For these studies, we expressed
Med13-HA from a single-copy plasmid in
med13∆ cells. These studies revealed that
both the wild type and the Med13T210A derivative were still degraded following
0.4 mM H2O2 stress (Supplemental Figure
Grr1
FIGURE 2: SCF
mediates Med13 degradation following H2O2 stress. (A) Model of the
Grr1
S1, C, D, and quantitated in E), indicating
SCF . (B) Wild-type (RSY10) and grr1∆ cells (RSY1770) harboring Med13-HA (pKC801) were
that T210 phosphorylation is not necessary
treated with 0.4 mM H2O2 for the time points indicated and Med13 levels were analyzed by
Western blot. (C) Top panel: RSY1798 (MED13-myc::KAN) was treated with 0.4 mM H2O2 for the for oxidative stress–induced destruction of
time points indicated and Med13 levels were analyzed by Western blot. Tub1 levels were used
Med13. Furthermore, consistent with our
as loading controls. Bottom panel: RSY1771 (grr1∆::HIS3 MED13-myc::KAN) harboring
previously published results with endogeADH1PRO-grr1∆L was analyzed as for RSY1798. Tub1 levels were used as loading controls.
nously tagged Med13-myc (Khakhina et al.,
(D) Yeast two-hybrid analysis of Med13 and Grr1 derivatives. Y69a cells harboring Med132014), Med13-HA degradation is not deactivating domain plasmid (pKC800) and either pAS2, pAS-Grr1, or pAS2-Grr1∆L binding
pendent on new protein synthesis, as it is
domain plasmids were grown on –LEU, –TRP dropout medium to select for both plasmids (left
still observed following cycloheximide treatpanel) and on –TRP, –LEU, –HIS –ADE (middle panel), and –TRP, –LEU, –HIS, –ADE +3-AT (right
ment (Supplemental Figure S1C).
panel) to test for Med13-Grr1 interaction.
We next employed Y2H assays to identify the Med13 region able to interact with
Grr1. Med13 has structured head and tail domains flanking a large
With the grr1∆L mutant bait, an interaction is detected selecting for
IDR (Toth-Petroczy et al., 2008; Figure 3A). A series of Gal4ADthe dual HIS3 and ADE2 reporter genes, but colony formation is
Med13 constructs that span the length of Med13 were built and
uneven (middle panel) or absent in the presence of 3-AT (right
tested for their ability to interact with Gal4BD-Grr1. The results repanel). Taken together with the increased stability of Med13 obvealed that the Grr1 interaction domain lies within the unstructured
served in grr1∆ cells, these results argue that Med13 is an SCFGrr1
domain, between amino acids 571 and 906 (Figure 3B, summarized
substrate.
in Figure 3A). To confirm that the Med13 degron lies within this region, we performed a
classical degron assay. The levels of the prey
Gal4AD-Med13571-906 fusion protein were
monitored following 0.4 mM H2O2 stress in
wild-type and grr1∆ cells. The results indicated that Med13571-906 was destroyed following oxidative stress in a Grr1-dependent
manner (Figure 3C). Taken together, these
results indicate that the SCFGrr1 degron lies
within the IDR.

FIGURE 3: The unstructured domain of Med13 binds Grr1. (A) ProteinPredict (Yachdav et al.,
2014) analysis of yeast Med13. Med13 contains amino- and carboxyl-terminal structured
domains separated by an intrinsic disordered domain (IDR). Grr1 and Med13 interaction regions
are indicated below the schematic. ± = qualitatively reduced binding (B). Med13-Grr1 Y2H
analysis. Y69a cells harboring pAS-Grr1 and the indicated Gal4AD-Med13 subclone were
streaked on media selecting for plasmid maintenance (left) or induction of the ADE2 and HIS3
reporter genes (right) by Y2H interaction. (C) Wild-type (RSY10) and grr1∆ (RSY1770) cells
harboring the minimal Med13 interaction domain expression plasmid (Gal4AD-Med13571–906)
were treated with 0.4 mM H2O2 for the time points indicated and Med13571–906 levels were
analyzed by Western blot. Pgk1 levels were used as loading controls.
Volume 29 February 1, 2018

The Med13 intrinsic disordered region
binds cyclin C
As cyclin C nuclear release represents an important step toward entering the cell death
pathway, we next sought to identify the
Med13 region that binds cyclin C, using twohybrid strategies. However, the yeast cyclin
C self-activates when tethered to a yeast
two-hybrid (Y2H) bait protein (Cooper et al.,
1997). Therefore, we used the human cyclin
C, as it does not self-activate two-hybrid
SCFGrr1-mediated degradation of Med13
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that cyclin C binds the same region of
Med13’s large IDR that is recognized by
SCFGrr1.

The Med13 intrinsic disordered region
is sufficient to retain cyclin C in the
nucleus

FIGURE 4: The Med13 IDR binds cyclin C. (A) Y2H analysis of the human cyclin C DNA–binding
domain plasmid (pSW108) and the indicated Gal4AD-Med13 subclone derivatives. The numbers
indicate the amino acids remaining in the activation domain plasmids. Transformants were
patched onto either –LEU, –TRP (–L–T) or –HIS –ADE –LEU –TRP (–H–A–L–T) to select for
plasmid maintenance or Y2H interaction, respectively. (B) Western blot analysis of pull-down
assays with His6-human cyclin C and GST-Med13742–844 (DS30). The load control contains 1/10 of
the input. Single and double asterisks represent cleaved GST and cross-reaction between
anti-GST antibody and human cyclin C, respectively. Molecular weight markers (kDa) are
indicated. (C) As in B except that yeast cyclin C was used. (D) Western blot analysis of pull-down
assays with GST yeast cyclin C and His6-Med13571–650 (DS22). The load control contains 1/50 of
the input. Molecular weight markers (kDa) are indicated.

reporter genes (Krasley et al., 2006). Using this approach, we
found that the same region associating with Grr1 (amino acid residues 571–906) also bound cyclin C (Figure 4A; summarized in
Figure 3A). To confirm these results, as well as to address if this
interaction is direct, we used a pull-down approach. We expressed
a central region of the Med13 interaction domain (amino acid residues 742–844) as a GST fusion protein. GST-Med13742-844 was
passed over a cobalt column on which Escherichia coli–prepared
human His6-cyclin C was bound. Following extensive washing,
bound proteins were eluted with imidazole and the presence of
GST-Med13742-844 was determined by Western blot analysis using
antibodies to His6 or human cyclin C. These results show that human cyclin C interacts with Med13742–844 (Figure 4B). The experiments were repeated using yeast cyclin C (Figure 4C). Although
the residual cleaved GST that was present in the GST-Med13 construct showed some interaction with yeast cyclin C, the full-length
construct showed a significantly stronger interaction. Confidence
was gained in this interaction being specific, as no interaction was
observed when GST alone was used in Figure 4, B or C. Interestingly, although amino acid residues 571–650 of Med13’s IDR can
associate with Grr1 (Figure 3B), this region does not associate with
cyclin C (Figure 4D). Thus, taken together, these results indicate
366 | D. C. Stieg et al.

To determine whether yeast cyclin C also
associates with the same region of Med13’s
IDR in vivo, we asked whether this region
(Med13571–906) is sufficient to retain cyclin C
in the nucleus in the absence of stress. To
address this question, mitochondrial morphology and subcellular localization of a
functional cyclin C-YFP (Cooper et al.,
2012) were monitored in unstressed
med13∆ cells harboring either a vector
control or one of four Gal4AD-Med13 fusion proteins. As expected, cyclin C was
predominantly cytoplasmic and colocalized with fragmented mitochondria in the
vector control (Figure 5A, top row, quantitated in Figure 5B, and see Supplemental
Figure S2 for DAPI stained images). Similarly, expression of Gal4AD-Med13571–650
was unable to retain cyclin C in the nucleus
or prevent mitochondrial fragmentation
(second row). However, cells expressing
either Gal4AD-Med13571–906, Gal4ADMed13651–906, or Gal4AD-Med13742–844 exhibited both nuclear retention of cyclin C
and fused mitochondria. Taken together
with the pull-down assays, these results
suggest that Med13742–844 is sufficient to
retain yeast cyclin C in the nucleus.

Cdk8 phosphorylation primes Med13
for destruction

SCF substrates are typically recognized
following phosphorylation of the degron.
However, many substrates require two phosphorylation marks: one
to “prime” the substrate and another that represents the trigger for
ubiquitylation (reviewed in Ang and Wade Harper, 2005). Previous
work revealed that protein kinase A (PKA) phosphorylates Med13 on
Serine 608 and 1236 (Chang et al., 2004). However, a derivative mutated for both phosphor acceptor sites (Med13S608A,S1236A-HA) was
still destroyed with kinetics similar to wild type (Supplemental Figure
S3A), indicating that PKA phosphorylation is not required for Med13
degradation following H2O2 treatment. Consistent with this result,
Med13S608A,S1236A-HA complements the aberrant mitochondrial morphology exhibit by med13∆ cells (Supplemental Figure S3B).
In addition to PKA, cyclin C-Cdk8 phosphorylates Med13 in human cells (Knuesel et al., 2009b; Poss et al., 2016) suggesting the
possibility that Cdk8 represents the priming kinase. To test this
model, Med13 destruction kinetics were monitored in a cnc1∆ null
strain transformed with either the wild-type CNC1 gene or the vector control. These experiments indicated that cyclin C-Cdk8 kinase
is necessary for Med13 destruction (Figure 6A and quantified in
Supplemental Figure S4A). Our previous studies showed that Slt2
phosphorylates cyclin C on Ser266 following H2O2, and this modification is required for its release from Med13 and translocation to
the cytoplasm (Jin et al., 2014). Therefore, one possibility is that
Molecular Biology of the Cell

FIGURE 5: The unstructured domain of Med13 retains cyclin C in the nucleus. (A) Fluorescence microscopy of mid–log
phase med13∆ cells (RSY1701) harboring the Gal4AD-Med13 construct indicated or a vector control (pACT2) and both
cyclin C-YFP and DsRed mitochondrial targeting (mt-DsRed) plasmids. Blue boxes indicated enlarged regions of the
image. Bar = 10 µM. (B) The percentage of the population of cells in A displaying at least three cyclin C-YFP foci in the
cytoplasm (top panel) or fragmented mitochondria (bottom panel) is quantified (mean ± SEM). At least 200 cells were
counted per time point from three individual isolates. *p < 0.05 difference from vector control.

cyclin C release is a prerequisite for Med13 destruction. Consistent
with this possibility, Med13 was protected from destruction in a
cnc1∆ mutant harboring a plasmid expressing cyclin CS266A (Figure
6A, right panel). These results indicate that cyclin C phosphorylation by Slt2 is also required for Med13-HA destruction (see below).
The results just presented indicated that the cyclin C-Cdk8 kinase is required for Med13 destruction in response to oxidative
stress. Consistent with this, Med13 is protected from degradation in
cells harboring kinase dead cdk8 as the only source of this enzyme
(Khakhina et al., 2014). As cyclin C-Cdk8 is active in unstressed cells,
these results suggest that this kinase could prime the degron for
recognition by SCFGrr1. To test this model, we attempted to perform
in vitro kinase assays with cyclin C-Cdk8 and Med13571–906 as the
substrate. Unfortunately, we were unable to get these assays to
work. Thus we decided to examine the phosphorylation state of the
Med13 degron derivative (GalADMed13571–906) using the Phos-Tag
SDS–PAGE system, which severely retards the movement of a
phosphorylated peptide (Kinoshita et al., 2006). Protein extracts
prepared from unstressed wild-type or cdk8∆ cultures harboring
GalADMed13571–906 were subjected to Phos-Tag Western blot analysis. The results revealed the presence of a slower migrating band in
the wild-type extract that was missing in the cdk8∆ sample (Figure
6B). This indicates that Cdk8 is required for Med13 phosphorylation
in unstressed cells.
Volume 29 February 1, 2018

To test whether cyclin C-Cdk8 activity was required before or after oxidative stress, a Cdk8-N-end rule degron was constructed.
This system takes advantage of the rapid turnover of proteins that
contain arginine as the amino terminal residue (Bachmair et al.,
1986; Varshavsky, 1992; Gnanasundram and Kos, 2015). The Cdk8N-end rule construct is under the control of a doxycycline-repressible promoter, so that the administration of doxycycline coupled with
the rapid turnover of the Cdk8-N-end rule fusion protein results in
rapid depletion of Cdk8 from yeast cells (Figure 6C). To test the execution point for Cdk8 phosphorylation, a mid–log culture expressing Med13-HA and Cdk8-N-end degron was untreated or treated
with doxycycline for 1 h prior to H2O2 addition to ensure Cdk8 depletion. A time course was conducted and samples were collected,
extracts prepared, and Med13-HA levels monitored by Western
blot analysis. These studies revealed that Med13-HA levels were
reduced similarly in both cultures (Figure 6D), indicating that Cdk8
function was required before oxidative stress. Taken together, these
results are consistent with a model in which Cdk8 phosphorylation
primes Med13 for degradation.

The CWI pathway is required for reactive oxygen
species–mediated destruction of Med13
The CWI signal transduction pathway is the major MAPK pathway in
yeast that transmits the reactive oxygen species (ROS) stress signal
SCFGrr1-mediated degradation of Med13
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above. These experiments revealed enhanced phosphorylation of
Med13571–906 above background that was dependent on a functional kinase (Figure 7C), indicating that Slt2 directly regulates
Med13 stability. Finally, we asked whether Slt2 activation was sufficient to induce Med13 destruction or whether another stress signal
was required. To address this question, Med13-HA levels were monitored in an unstressed culture expressing a constitutively active allele of the upstream MAPKKK BCK1 (BCK1-20). Mid-log cultures
expressing BCK1-20 exhibited dramatically reduced Med13-HA levels compared with vector controls (Figure 7D). These results indicate
that the CWI pathway is both necessary and sufficient to induce
Med13 destruction. Finally, to test the epistatic relationship between BCK1-20 and cdk8∆ alleles, the experiment just described
was repeated in a cdk8∆ background. Western blot analysis revealed that Cdk8 was required for BCK1-20-induced Med13 destruction in unstressed cells (Figure 6D). Taken together, these results indicate that Slt2 activation is necessary for H2O2-mediated
Med13-HA degradation and that this signal requires Cdk8 activity.
These results are consistent with a three-step model for initiating the
Med13 destruction pathway (see the Discussion).

FIGURE 6: Cyclin C-Cdk8 directly stimulates Med13 proteolysis.
(A) Mid-log cnc1∆ cultures (RSY391) harboring either wild-type CNC1
(pKC337), vector (pRS314), or cnc1S266A (pLR166) expression plasmids
and pKC803 (CEN, Med13-HA) were subjected to an H2O2 timecourse experiment. Pgk1 levels were used as loading controls.
(B) Phos-tag gel analysis of pDS8 (Gal4AD-Med13571–906) in unstressed
wild-type (RSY10) or cdk8∆ (RSY1796) cultures. Arrow indicates
phosphorylated Med13571–906 species. Molecular weight markers
(kDa) are indicated. (C) RSY2066 harboring the Ubi-Ile3-Cdk8-HA
expression plasmid (pCM1888) were grown to mid–log phase and
doxycycline added for the indicated times. Cdk8-HA levels were
monitored by Western blot analysis. Tub1 levels were monitored for
loading control. (D) RSY2066 harboring pCM1888 and Med13-HA
(pKC803) were grown to mid–log phase, the culture split, and
doxycycline added to one for 1 h. Both cultures were then treated
with 0.8 mM H2O2 and Med13-HA degradation monitored as
previously described. Tub1p was monitored for loading control.

to transcription factors (Staleva et al., 2004). To facilitate cyclin C
nuclear release, the CWI employs two MAPKs, Slt2 and its pseudokinase paralogue Kdx1. Slt2 phosphorylates cyclin C on Serine 266
to induce cytoplasmic relocalization (Cooper et al., 2012; Jin et al.,
2013, 2014), while Kdx1 functions through an unknown mechanism
(Jin et al., 2015). To address the question of whether Kdx1 and/or
Slt2 is required for Med13 degradation, we examined Med13-HA
degradation kinetics in wild-type and slt2∆ or kdx1∆ single-mutant
cultures following 0.4 mM H2O2 stress. As slt2∆ mutants are temperature-sensitive, these experiments were conducted at 23°C. The
results show that Med13-HA was degraded in wild-type or kdx1∆
cells but stable in the slt2∆ mutant (Figure 7A, quantified in Supplemental Figure S4B). These results indicate that unlike cyclin C, only
Slt2, but not Kdx1, is required for Med13 destruction. Repeating this
experiment with cells expressing a kinase-dead version of SLT2
(slt2K54R) produced similar results (Figure 7B), indicating that Slt2 kinase activity is required for Med13 proteolysis. To investigate
whether the role of Slt2 in Med13 degradation was direct, in vitro
kinase assays were performed using activated Slt2-HA or the kinasedead derivative (Slt2K54R-HA; Kim et al., 2008) immunoprecipitated
from yeast extracts. The immunoprecipitate was incubated with the
E. coli prepared Med13 degron (amino acids 571–906) described
368 | D. C. Stieg et al.

Slt2 and Cdk8 phosphorylation of the intrinsic disordered
region is required for Med13 destruction
IDRs confer conformational flexibility on proteins that are often targets of posttranslational modifications (Diella et al., 2008). Notably,
IDRs are enriched in phosphorylation sites, raising the possibility
that they are substrates for multiple kinases (Collins et al., 2008). As
our data indicate that Cdk8 and Slt2 are required for Med13 degradation, we next asked if the sites they phosphorylate lie within the
same IDR of Med13 that associates with Grr1 and cyclin C (amino
acids 651–906). Slt2 and Cdk8 are both proline-directed kinases that
preferentially phosphorylate the consensus sequences PX(S/T)P and
S/T-P-X-K/R (where X is any amino acid), respectively. They also can
phosphorylate the minimal consensus sequence S/T-P (Nigg, 1993).
Med13651–906 contains a conserved Slt2 consensus sequence at position 748 that has been identified as potential phosphorylation site in
two genomic screens (Albuquerque et al., 2008; Holt et al., 2009)
as well as four additional TP sites (Figure 8A). Thus, to address
whether these kinases phosphorylate the five S/T-P sites in Gal4ADMed13651–906 fusion protein, its degradation was monitored following H2O2 stress in wild-type, slt2∆ and cdk8∆ cells. The results show
that Gal4AD-Med13651–906 fusion protein is stable in either slt2∆ or
cdk8∆ cells (Figure 8B). These results are consistent with a model
where the Med13 phosphodegron is targeted by both Cdk8 and
Slt2. Consistent with the Y2H data presented in Figure 3B, the phosphodegron is stable in grr1∆ cells (Figure 8C). If the Med13 phosphodegron is regulated by two kinases, then two separate S/T-P
sites within the degron should stabilize the protein. To test this, wildtype cells harboring either a wild-type Gal4AD-Med13742–844 fusion
protein or mutant derivatives were subjected to 0.4 mM H2O2 stress
and analyzed as described above. As anticipated, the smaller
Gal4AD-Med13742–844 fusion protein that contains all five S/T-P sites
was still degraded in wild-type cells (Figure 8C). Interestingly, the
S748A, T781A, and T803A mutants were also degraded, with the
same kinetics as wild type (Supplemental Figure S4C). In addition,
the double mutants (T781A, T803A and S748A, T781A) were also
degraded with wild-type kinetics (Figure 8, D and E). However, the
T835A, T837A double mutant was significantly more stable than the
wild type (Figure 8, C and E), suggesting that these sites are needed
for Med13 degradation. Taken together, these results suggest that
both kinases have to be active for SCFGrr1 to recognize this 100–
amino acid phosphodegron at positions T835 and T837.
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order most likely facilitates multiple kinases
regulating a protein within a small region.
We identified a small region (amino acids
742–844) within the IDR of Med13 that acts
as a communication hub. This region is sufficient to retain cyclin C in the nucleus, associates with Grr1, and contains the Med13
phosphodegron that is primed by Cdk8 and
activated by Slt2 following oxidative stress
exposure. This dual kinase requirement provides the cell with a mechanism to integrate
multiple input signals into a single readout.

FIGURE 7: Slt2 directly stimulates Med13 destruction. (A) Wild-type (RSY10), kdx1∆ (RSY1736)
and slt2∆ (RSY1006) cultures expressing pKC801 (CEN, Med13-HA) were grown to mid–log
phase (0 h) and then treated with 0.4 mM H2O2 for the indicated times. Med13-HA levels were
determined by Western blot analysis. (B) As in A except that the slt2∆ cells expressed a kinase
dead SLT2 mutant (slt2K54R) plasmid. (C) Top panel: Slt2-HA or Slt2K54R-HA (kinase dead) was
immunoprecipitated from extracts prepared from cells treated for 60 min with 5 mM sodium
orthovanadate was mixed with Med13571–906 and radioactive ATP as indicated. All reactions were
conducted in duplicate and then separated by SDS PAGE and subject to autoradiography.
Med13571–906 is indicated by the arrowhead. Bottom panel: Coomassie stained gel showing the
Med13571–906 input used in the kinase assays. (D) Wild-type (RSY10) or cdk8∆ (RSY1796) mutant
cells expressing either an empty vector control or the hyperactive allele of BCK1 (BCK1-20) and
MED13-HA (pKC803) were grown to midlog and Med13-HA levels determined by Western blot
analysis. Tub1 served as a loading control.

DISCUSSION
Communication between organelles is critical to coordinate the cellular response to a variety of external or internal signals, including
oxidative stress. The data presented here and in previous publications (Cooper et al., 1997, 2014; Krasley et al., 2006; Jin et al., 2013,
2014, 2015; Khakhina et al., 2014; Wang et al., 2015) have revealed
that the CKM plays a key role in both yeast and mammalian cells.
Previously, we reported that cyclin C, but not Cdk8, translocates
from the nucleus to the mitochondria following oxidative stress in
both yeast and mammalian cells. At the mitochondria, cyclin C associates with the fission machinery to induce fragmentation and directs programmed cell death (Cooper et al., 2012, 2014; Wang
et al., 2015). Therefore, releasing cyclin C from the nucleus represents an important step determining whether the cell initiates the
RCD pathway or not. Importantly, we found that the nuclear anchor
for cyclin C, Med13, is destroyed in response to oxidative stress,
providing a mechanism for orchestration of cyclin C nuclear release
(Khakhina et al., 2014). Interestingly, Med12 is neither required for
this response (Khakhina et al., 2014) nor destroyed following H2O2
stress (Supplemental Figure S4D). In this report, we provide the
molecular details on how Med13 destruction is triggered to operate
this important molecular switch in yeast. First, Med13 proteolysis is
mediated by the ubiquitin ligase SCF and the specificity factor Grr1.
Several studies in yeast and higher eukaryotes found that SCF substrates require a complex interplay between multiple kinases to
generate the requisite phosphodegron on the substrate (reviewed
in Ang and Wade Harper, 2005). For example, Cdk1 acts as a priming kinase for Cdc5 (Asano et al., 2005; Yoshida et al., 2006), whereas
Cdc5 acts as a priming kinase for Wee1 (Watanabe et al., 2004). In
all cases, the priming kinase first phosphorylates the substrate, while
the second kinase completes the formation of the phosphodegron
by modifying residues that are recognized by the SCF. This has led
to the current model, in which priming phosphorylations create
docking sites for downstream kinases. Moreover, local structural disVolume 29 February 1, 2018

Med13 phosphodegron activation
requires a three-step process

Our results indicate that cyclin C-Cdk8
provides the priming signal for Med13 destruction (Figure 9, Step 1). Although technical reasons prevented us from addressing
whether this activity is direct or indirect, four
independent experiments support a model
of this as a direct phosphorylation event: 1)
The observation that Med13651–906 was not
destroyed following H2O2 stress in cdk8∆
cells (Figure 8B). 2) The observation of a
slower migrating band seen in Phos-Tag
SDS–PAGE analysis of unstressed in wildtype extracts that was missing in the cdk8∆
sample (Figure 6B). 3) The end-N rule experiments conducted in
Figure 6, C and D, also revealed that Med13-HA levels were reduced regardless of the presence of Cdk8 after stress. 4) Last, in vitro evidence revealed that cyclin C interacts directly with this region
of Med13 (Figure 4, B and C), which would position the kinase with
direct access to the Med13 degron. Thus, taken together, these results suggest that Cdk8 phosphorylation primes Med13 for degradation, most likely by a direct event. Consistent with this, human
Cdk8 directly phosphorylates human Med13 on S749, which lies in
the intrinsic disorder domain in what appears to be a nonconserved
residue compared with yeast (Poss et al., 2016). This requirement
may be necessary to inform the cell that Med13 is in the Cdk8 module and its destruction will lead to cyclin C release and Cdk8 inactivation. Slt2 activation by oxidative stress provides the trigger mechanism that commits the cell to destroying Med13 and releasing
cyclin C from the nucleus (Step 3). This event accomplishes two
goals. First, removing cyclin C and destroying Med13 inhibits the
repressor activity of Cdk8 for several stress-responsive genes, including chaperones (e.g., SSA1), anti-oxidants such as catalase
(CTT1), and the multi-stress-responsive gene DDR2 (Cooper et al.,
1997, 2012; Holstege et al., 1998). In addition, Slt2 activation stimulates several transcription factors, such as Rlm1, which is required for
the transcriptional arm of the stress response (Dodou and Treisman,
1997; Watanabe et al., 1997; Jung et al., 2002). Therefore, Slt2 activation both stimulates transcriptional activators and inhibits repressors. By releasing cyclin C, the cell is able to transmit the stress signal to the mitochondria. We have previously demonstrated that
cyclin C–induced fission alone is not sufficient to induce cell death,
but does make cells hypersensitive to oxidative stress (Khakhina
et al., 2014). Therefore, cyclin C release poises the cell to initiate
RCD, but additional regulatory layers exist. Unlike other priming/
trigger two-kinase degron phosphorylation switches, we have
identified an additional step in the system regulating Med13. Specifically, Slt2 also modifies cyclin C on S266, which promotes its
SCFGrr1-mediated degradation of Med13
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sary for complete cyclin C release. Not exclusive of this model, another possibility is
that Med13 destruction prevents the reaccumulation of cyclin C in the nucleus after its
cytoplasmic translocation. In this model,
Med13 proteolysis fixes the decision of cyclin C release thus directing a complete
transcriptional and mitochondrial response
to oxidative stress.

The Med13 intrinsic disordered region
is a communication hub
It has recently been suggested that IDRs
play important roles in protein:protein communication, as they provide a flexible interaction surface to multiple partners (Wright
and Dyson, 2015). Using two different protein structure prediction algorithms, IUPred/
ANCHOR and Phyre2 (Dosztanyi et al., 2005,
2009; Kelley et al., 2015), Med13 has a large
IDR spanning the middle of the protein
(amino acids residues 307–906 and Supplemental Figure S5, A and B). Although not
conserved in amino acid sequence, it is notable that the position and presence of
Med13’s IDR is conserved throughout three
kingdoms (Nagulapalli et al., 2016). Also
conserved is the observation that Med13 is
the CKM member that brings this kinase
module in contact with the Mediator complex (Knuesel et al., 2009a). This suggests a
model in which the IDR of Med13 provides
conformational plasticity to the CKM, which
is important for bringing the kinase and
other proteins into contact with different mediator members on a pro re nata basis. This
idea is consistent with the results presented
here, in which we show that the IDR of
Med13 can bind to cyclin C before stress
and Grr1 after. Although speculative, taken
together, this suggests a model in which
FIGURE 8: The Med13 IDR contains the phosphodegron. (A) Map of Med13 showing the
Med13 IDR is conserved functionally and
location of potential Cdk and MAPK sites within the IDR. (B) Wild-type (RSY10), slt2∆ (RSY1737),
may contain signature motifs that are imporAD
651–906
and cdk8∆ (RSY1796) cultures expressing pDS16 (Gal4 -Med13
) were grown to mid–log
tant for protein binding. Consistent with this
phase (0 h) and then treated with 0.4 mM H2O2 for the indicated times. Med13651–906-HA
idea is the observation that two other conlevels were determined by Western blot analysis. Pgk1 levels were used as a loading control.
served proteins that regulate transcription
(C, D) Wild-type (RSY10) cultures harboring wild-type Gal4AD-Med13742–844 (pDS32) or various
point mutations as indicated were grown to mid–log phase (0 h) then treated with 0.4 mM H2O2 (CCR4-NOT4 and TFIIS) also bind to the IDR
for the indicated times. Med13-HA levels were determined by Western blot analysis. Pgk1 levels of yeast Med13, but in a different location
were used as a loading control. The Gal4AD-Med13742–844 levels were also monitored in the
(Supplemental Figure S5; Liu et al., 2001;
grr1∆ strain. (E) Degradation kinetics of the Gal4AD-Med13742–844 constructs shown in C and D.
Wery et al., 2004). Such a signature could be
a MoRF, which is defined as a short binding
dissociation from Med13 (Jin et al., 2014). Our finding that the
region located within a longer intrinsically disordered region that
S266A mutation protects Med13 from destruction is consistent
binds to protein partners via disorder-to-order transitions (Kottawith a model in which S266 modification disrupts cyclin C–Med13
Loizou et al., 2013). ANCHOR analysis (Dosztanyi et al., 2009) preinteraction (Step 2), allowing Slt2 access to the phosphodegron.
dicts that the IDR of Med13 has many such domains, with two lying
Taken together, our model predicts a three-step system that conwithin the cyclin C binding region (residues 742–844, Supplemental
trols Med13 stability and cyclin C nuclear release.
Figure S5A). As additional factors are identified that bind the Med13
If cyclin C phosphorylation is sufficient to initiate cyclin C nuclear
IDR, the rules that govern these interactions may become better
release, then why would it be important to completely destroy
understood.
Med13? First, our results indicate that S266 phosphorylation is caThe need to understand the role that Med13 IDR plays in protein
pable of stimulating only partial release of cyclin C in unstressed
communication has become important in the past decade, as in
cells (Jin et al., 2014). Therefore, Med13 destruction may be neceshumans truncating or loss-of-function mutations in MED13L, a
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FIGURE 9: Three-step model of cyclin C release from Med13
following H2O2 stress. Step 1: Cdk8-cyclin C kinase phosphorylates
Med13 in unstressed cells to provide the priming modification for this
degron. Step 2 requires stress-activated Slt2 that phosphorylates
cyclin C on S266 leading to dissociation of cyclin C from Med13. This
event allows Slt2 access to the phosphodegron to deliver the trigger
modification leading to Med13 recognition by SCFGrr1 and its
destruction (Step 3).

paralogue of MED13 (Muncke et al., 2003), results in MED13L haploinsufficiency syndrome. This syndrome is complex and presents
with a range of symptoms including congenital heart and neurodevelopmental defects, severe neurocognitive deficiencies, and facial
dysmorphism (Adegbola et al., 2015; van Haelst et al., 2015; Asadollahi et al., 2017; Yamamoto et al., 2017). Interestingly many of
these mutations lie in the IDR of MED13L (Asadollahi et al., 2017). In
yeast, a hallmark of med13∆ cells is that they are respiratory deficient, which is dependent on cyclin C nuclear release (Khakhina
et al., 2014). Thus, it would be anticipated that a strain deleted for
Med13 residues 742–844 would have a similar phenotype. Taken
together, these studies emphasize the need for further analysis of
both yeast and human Med13 IDRs to understand the molecular
details of how this region contributes to Med13 function.

Role of SCFFbw7 and Med13 in higher eukaryotes
following stress
Our previous studies described the conserved role of cyclin C in
stressed and unstressed cells (Cooper et al., 2014; Wang et al.,
2015). However, differences are observed between yeast and humans in cyclin C regulation. In yeast, all of cyclin C is released into
the cytoplasm, followed by its destruction by the Not1 ubiquitin
ligase. Conversely, only ∼10% of total cyclin C is released from the
nucleus in mammalian cells following oxidative stress, and we do
not detect any significant changes in its overall protein levels
(Wang et al., 2015). Steady state turnover of the human Med13 is
directed by the analogous SCF ubiquitin ligase by a homologue of
Grr1, called Fbw1 (Davis et al., 2013). As Med13 tethers the Cdk8
module to the Mediator complex (Knuesel et al., 2009a), Med13
turnover determines the promoter residency of the module and
therefore impacts transcriptional regulation. However, we found
that the phosphodegron directing the turnover of Med13 in human
cells (T326) is not required for stress-induced destruction of Med13
in yeast. These results suggest either that a different degron system is employed in these two systems or that stress-induced destruction is regulated differently than that observed under normal
growth conditions. Consistent with this is the observation that Cdk
substrates are often clustered in regions of intrinsic disorder (reviewed in Enserink and Kolodner, 2010). However, similar to other
IDRs, their exact position in the protein is often poorly conserved
in evolution, indicating that precise positioning of phosphorylation
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may not be required to permit a shared function (reviewed in
Enserink and Kolodner, 2010). Thus, it is possible that following
oxidative stress in human cells, a similar two-kinase mechanism
could regulate Med13 degradation. In support of this model,
phosphorylation by two kinases has been observed for other
SCFFbw7 substrates (Akhoondi et al., 2007) including oncogenic
transcription factors. This has led to Fbw7 being classified as a tumor suppressor (reviewed in Welcker and Clurman, 2008). Fbw7
degrades numerous oncogenic transcription factors (e.g., Myc,
Notch, and Jun), as well as other proteins that contribute to carcinogenesis. As cyclin C has also recently been given this tumor suppressor designation (Li et al., 2014), it is imperative to understand
the relationship between these proteins following stress in higher
eukaryotes.

MATERIALS AND METHODS
Yeast strains and plasmids
All experiments, except the Y2H assays, were performed on the
S. cerevisiae W303 strain RSY10 (Strich et al., 1989) and are listed
in Supplemental Table S1. The Y2H assays were performed on
PJ69-4a (James et al., 1996). In accordance with the Mediator
nomenclature unification effort (Bourbon et al., 2004), cyclin C
(SSN8/UME3/SRB11) and Cdk8 (SSN3/UME5/SRB10) will use the
CNC1 and CDK8 gene designations, respectively. For reference, the
human cyclin C gene name is CCNC. The cnc1∆, cdk8∆, med13∆,
slt2∆, kdx1∆, and kdx1 slt2∆ strains have been previously described
(Cooper et al., 1997, 2014; Krasley et al., 2006; Jin et al., 2014). The
grr1∆ strain RSY1770 and the myc-,tagged Med12 strain (RSY1787)
were constructed using gene replacement methodology as described (Longtine et al., 1998). The MED13-13myc allele was generated in RSY1770 to create RSY1771 using the same methodology.
RSY2066 was made by integrating pMK634 (Gnanasundram and
Kos, 2015) into the CDK8 locus of RSY10. The strain was then transformed with pCM188 (Gari et al., 1997), which contains the TET activator on a plasmid. The yeast hybrid strain PJ69-4a was obtained
from the Yeast Resource center, courtesy of a gift from S. Fields
(University of Washington). All cells were grown at 30°C, apart from
slt2∆ and slt2∆ kdx1∆, which were grown at 23°C.
All plasmids used in this study are listed in Supplemental Table
S2. The wild-type epitope tagged plasmids pHY1066 (MED13-HA,
2 µ), pKC337 (ADH1Pro-cyclin C-myc), pUM511 (GPD1Pro-CDK8HA), and pBK38 (ADH1Pro-CNC1-YFP) are functional and have been
described previously (Cooper et al., 1997, 2012; Cooper and Strich,
1999; Chang et al., 2004; Jin et al., 2013). pLR141 was made
by cloning the ADH1Pro-CNC1-myc, CYCTerm from pKC337 into
pRS426. The 2 µ MED13-HA plasmids (PHY1066 and PHY1089) and
were a gift from P. Herman (Ohio State University) (Chang et al.,
2004). The wild-type MED13 centromere–based plasmids pKC801
and pKC803 were made by PCR cloning the ADH1 promoter
MED13-3HA ORF and the MED13 terminator from PHY1022 into
pRS316 and pRS315, respectively. Site-directed mutagenesis (New
England Bio-Rad Q5) was used to create plasmids harboring amino
acid mutations, except for DS36 which was made using the ChangeIT kit by Affymetrix. The CNC1S266A and the SLT2K54R (a gift from D.
Levin, Boston University) have been described previously (Kim et al.,
2008; Jin et al., 2014). The MED13 Y2H plasmids were constructed
by PCR cloning from pHY1022 into the Xho1 site of the Gal4 activating domain plasmid pACT2. Likewise, the human cyclin C Y2H Gal4
binding domain plasmid pSW108 was made by PCR cloning of
cyclin C cDNA amplified from pEGFP-cyclin C (unpublished data)
into Nco1-digested pAS2. The GST-MED13 fusion plasmid was made
by PCR cloning from PHY1022 into pGEX4T-1. Oligonucleotide
SCFGrr1-mediated degradation of Med13
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sequences were used to make plasmids, and strains are available
upon request. In short, all constructs were amplified from plasmid
DNA using Phusion Taq (Thermo) digested using NEB fast digest
restriction enzymes and ligated using Thermo fast ligase into their
respective vectors. All protein fusion constructs were sequenced
(Eurofins Genomics). Other plasmids that were used in this study
that have been previously described are listed in Supplemental
Table S2.

Cell growth
Yeast cells were grown in either rich, nonselective medium (YPDA) or
synthetic minimal medium (SC), allowing plasmid selection as previously described (Cooper et al., 1997). For all experiments, the cells
were grown to mid–log phase (∼6 × 106) before treatment with low
concentrations of 0.4 mM H2O2, as previously described (Jin et al.,
2013). Samples of 25 ml of cells were collected per time point and
washed in water; then the pellets were flash frozen in liquid nitrogen.
Y2H experiments were executed as described (Wang and Solomon,
2012). A sample of 10 mM 3-amino-1,2,4-triazole (3-AT) was added
to the selective plates to increase the stringency of the interactions.
E. coli cells were grown in LB medium with selective antibiotics. The
degron experiments described in Figure 5, D and E, were executed
as follows. In Figure 5D, cells (RSY2066) were grown to midlog and
samples removed at the time points shown for analysis of Ubiisoleucine::3HA-Cdk8 degradation after the addition of 2 µg/ml
doxycycline. In Figure 5E, RSY2066 was transformed with Med133HA plasmid (pKC803), grown to midlog, and split and into one
flask 2 µg/ml doxycycline was added. After 60 min, 0.8 mM H2O2
was added to both sets of cells and samples taken for NaOH lysis
and Western analysis as described below.

Western blot analysis
Tagged Med13 constructs were detected using NaOH lysis of cell
pellets as described by Zhang et al. (2011). In short, the frozen cell
pellets were defrosted on ice, resuspended in 2 M LiOAc on ice for
5 min, centrifuged, and then resuspended in 0.4 M NaOH for a further 5 min on ice. Thereafter, the pellets were resuspended in 100 µl
2X SDS loading dye (Cooper et al., 1997) and boiled for 5 min, and
15 µl was loaded onto a 6% SDS–PAGE gel (Novagen). For the
phos-tag gel (Figure 9B), proteins were prepared as just described
and analyzed on a 7.5% polyacrylamide gel containing 7.5 µM phostag (Wako Laboratory Chemicals) and 15 µM MnCl2. The proteins
were transferred to a nylon membrane (Millipore) using 10% methanol, 0.02% SDS, and 10X running buffer (Cooper et al., 1997). To
detect Med13-myc, Med12-myc, and Med13-HA, 1-in-5000 dilutions of either anti-myc (Roche) or anti-HA antibodies (Clontech)
were used. Tub1 and Pgk1 were visualized as previously described
(Tan et al., 2011), except that anti–alpha tubulin antibodies (12G10)
were obtained from the Developmental Studies Hybridoma Bank,
University of Iowa. Western blot signals were detected using either
goat anti-mouse or goat anti-rabbit secondary antibodies conjugated to alkaline phosphatase (Sigma) and the CDP-Star chemiluminescence kit (Tropix). Signals were quantitated by CCD camera imaging (Kodak). All degradation assays were performed more than
once. SEM were generated for each point and error bars are indicated on the graphs, which were generated using the GraphPad
Prism 7 program.

Fluorescence microscopy
YFP-cyclin C subcellular localization and mitochondrial morphology
were monitored as described previously (Cooper et al., 2012, 2014).
For all experiments, the cells were grown to midlog (6 × 106 cells/
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ml), treated with 0.4 mM H2O2 for the time points indicated, and
then analyzed by fluorescence microscopy. Cyclin C-YFP export
analysis was performed on cells fixed with 4% paraformaldehyde/3.4% sucrose for 1 h at room temperature. The cells were
washed three times in water and prepared for fluorescence microscopy as described previously (Guacci et al., 1997) using mounting
medium (10 mg/ml p-phenylenediamine, 50 ng/ml 4′,6-diamidino2-phenylindole [DAPI]) to visualize nuclei and prevent photo bleaching. Images were obtained using a Nikon microscope (Model E800)
with a 100× objective with 1.2× camera magnification (Plan Fluor
Oil, NA 1.3) and a CCD camera (Hamamatsu Model C4742). Data
were collected using NIS software and processed using Image Pro
software. All images of individual cells were optically sectioned
(0.2 µM slices at 0.3 µM spacing) and deconvolved, and the slices
were collapsed to visualize the entire fluorescent signal within the
cell. Cyclin C-YFP foci were scored as being cytoplasmic when three
or more foci were observed outside the nucleus. Mitochondrial fission assays were performed on live cells as described (Cooper et al.,
2014). In brief, mitochondrial fission was scored positive if no reticular mitochondria were observed that transversed half the cell diameter. Fusion was scored when cells exhibited one or more reticular
mitochondria the diameter of the cell. Fission and fusion was scored
for 200 cells from three independent isolates. Statistical analysis was
performed using Student’s t test, with p < 0.05 used to indicate
significant differences.

Pull-down assays and kinase assays
Purified proteins that were used in the pull-down assay (Figure 4B)
were made as follows. The GST constructs (DS30, GST hCCNC, and
GST alone) were transformed into the BL21 DE3 E. coli strain and
expression was induced with 0.5 M IPTG at 37°C for 3 h. Cell pellets
were resuspended in 50 ml GST lysis buffer (150 mM KCl, 50 mM
HEPES, pH 7.5, 1 mM βME) and sonicated (25 × 10 s bursts), and
the supernatant was recovered by centrifugation at 40,000 × g for
30 min. The supernatant was then added to 1 ml of washed glutathione beads (LifeTech) rotated at 4°C for 1 h. The unbound fraction
was removed from the beads by gravity flow. The beads were
washed twice with lysis buffer and the bound protein was eluted in
five 1 ml fractions with the elution buffer (lysis buffer supplemented
with 10 mM reduced glutathione). The protein-containing fractions
were pooled and then desalted using 4 ml Zebra7K desalting
columns that had been preequilibrated with the lysis buffer. The
protein fraction was supplemented with glycerol to a final concentration of 10% and stored at –80°C in small aliquots. His6 tagged
human or yeast cyclin C was purified the same way with the following exceptions. The lysis buffer (buffer A) was 500 mM KCl, 50 mM
HEPES, pH 7.5, 1 mM βME, and 20 mM imidazole. Talon beads
(Clontech) were used and washed with buffer B (150 mM KCl,
50 mM HEPES, pH 7.5, 1 mM βME , and 20 mM imidazole) and the
bound protein was eluted in elution buffer (150 mM KCl, 50 mM
HEPES, pH 7.5, 1 mM βME, and 500 mM imidazole). The desalting
columns were preequilibrated with the B buffer without imidazole.
The concentrations of all the recombinant proteins were determined by Bradford assay. The pull-down assays in Figure 4, B and C,
were performed using His6-tagged human or yeast cyclin C, respectively, as bait and GST-tagged Med13742–844 (DS30) as target. A
quantity of 500 nM cyclin C was mixed with 1 μM of Med13742–844 in
a final reaction volume of 250 µl with B buffer and incubated for 1 h
at room temperature. Bound protein was precipitated with 100 µl of
washed Talon beads and eluted using 500 mM imidazole. The protein mixture was resolved using SDS–PAGE and Western blotting
with either anti-GST (Abcam), anti-His (Bethal), or anti–human cyclin
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C antibodies (Bethal). Controls with only the target protein and no
bait protein were included in all the experiments. The pull-down
assays in Figure 4D were performed using 500 nM of either GST or
GST-tagged yeast cyclin C and 1 µM His6-Med13571–660 (DS22). The
proteins were incubated together in GST lysis buffer and incubated
at RT for 1 h. Then 100 μl of GSH beads (preequilibrated with GST
wash/lysis buffer) was added to the protein mixture and incubated
with rotation for 1 h. The beads were centrifuged for 30 s washed
twice with 500 μl of GST wash/lysis buffer. The protein mixture was
resolved using SDS–PAGE and Western blotting with either antiGST or anti-His antibodies.
The in vitro kinase assays were executed basically as described
by DeMille et al. (2015). Slt2-HA and Slt2K54R-HA kinases were immunoprecipitated from cells treated with 5 mM sodium orthovanadate for 60 min, which activates Slt2 (Martin et al., 2000). In short,
yeast extracts harboring the respective plasmids were made by resuspending cells in lysis buffer (20 mM HEPES, 10 mM KCl, 1 mM
EDTA, 1 mM ethylene glycol tetraacetic acid [EGTA], 50 mM NaCl,
10% glycerol, 1 mM β-mercaptoethanol, and cOmplete Protease
Inhibitor Cocktail Tablet, pH 7.4, with phosphatase inhibitors for
Cdk8-HA purification) and protein immunoprecipitation was conducted as previously described (DeMille et al., 2015), with anti-HA
magnetic beads (PierceTM)/anti-myc magnetic beads (Cell Signaling). Med13571–906 was purified from an E. coli BL21 DE3 strain induced with 0.5 mM IPTG for 5 h at 37°C using the 6X His-tagged
purification method previously described (DeMille et al., 2015). The
Slt2 in vitro kinase assay was conducted as previously described
(Carmody et al., 2010) by resuspending Slt2 beads in kinase buffer
(20 mM HEPES, 10 mM MgCl2, 100 μM Na3VO4, pH 7.5), with 20
μM ATP, 5 μCi of 32P-ATP, and purified Med13571–907. Reactions
were incubated at 30°C for 30 min.
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